| Metastasis-directed Therapy for Oligorecurrent Prostate Cancer (NCT05352178) | Universitaire Ziekenhuizen KU Leuven | 2022-04-20 |
| ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) (NCT04916613) | UNICANCER | 2022-04-19 |
| 68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis (NCT05627778) | Peking Union Medical College Hospital | 2021-11-01 |
| Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer (NCT04983095) | Karin Soderkvist | 2021-10-27 |
| A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer (NCT05067140) | Novartis Pharmaceuticals | 2021-09-02 |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide (NCT04335682) | Alliance Foundation Trials, LLC. | 2021-08-17 |
| A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA) (NCT04660617) | West China Hospital | 2021-08-01 |
| Dutch National Randomized Study: PSMA-PET/CT As a Triage Tool for Pelvic Lymph Node Dissection in Prostatectomy Patients (NCT05000827) | Canisius-Wilhelmina Hospital | 2021-07-28 |
| Telaglenastat + Talazoparib In Prostate Cancer (NCT04824937) | Massachusetts General Hospital | 2021-07-01 |
| Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (NCT04848337) | University of Michigan Rogel Cancer Center | 2021-05-25 |
| Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT04781374) | Beth Israel Deaconess Medical Center | 2021-05-21 |
| 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer (NCT04483414) | Dana Mathews | 2021-03-19 |
| HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT03850795) | Hinova Pharmaceuticals USA, Inc. | 2021-03-15 |
| An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum (NCT05384002) | Fondazione del Piemonte per l'Oncologia | 2021-02-24 |
| Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer (NCT04641078) | University Hospital, Ghent | 2021-02-12 |
| Metastatic Prostate Cancer Men's Attitudes Towards Treatment of the Local Tumour and Metastasis Evaluative Research (NCT04590976) | Imperial College London | 2020-12-03 |
| A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC (NCT04603833) | Jiangsu HengRui Medicine Co., Ltd. | 2020-12-02 |
| Molecular Profiling in Prostate Cancer (NCT04983628) | Hellenic Cooperative Oncology Group | 2020-10-01 |
| PROState Pathway Embedded Comparative Trial (NCT04400656) | Imperial College London | 2020-09-08 |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (NCT04478279) | Sapience Therapeutics | 2020-07-01 |
| The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer (NCT04179968) | Dana Mathews | 2020-01-27 |
| Checkpoint Inhibitors and SBRT for MCRPC (NCT05655715) | Herlev and Gentofte Hospital | 2019-11-25 |
| Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (NCT03784755) | Canadian Cancer Trials Group | 2019-11-15 |
| MSG Use With 18F-DCFPyL PET/CT Imaging (NCT03693742) | British Columbia Cancer Agency | 2019-11-04 |
| Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. (NCT04116775) | Julie Graff, MD | 2019-10-30 |
| National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients (NCT04086290) | Peter Busch Østergren | 2019-10-10 |
| Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer (NCT04030338) | Memorial Sloan Kettering Cancer Center | 2019-07-19 |
| ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer (NCT04028388) | Modra Pharmaceuticals | 2019-07-17 |
| A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer (NCT04019327) | Memorial Sloan Kettering Cancer Center | 2019-07-11 |
| Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer (NCT03833921) | Martha Mims | 2019-05-23 |
| REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer (NCT03951831) | Mark Stein | 2019-05-16 |
| Safety and Pharmacokinetics of ODM-209 (NCT03878823) | Orion Corporation, Orion Pharma | 2019-04-17 |
| A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer (NCT03843918) | Laekna Limited | 2019-04-05 |
| Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone (NCT03988686) | Fudan University | 2019-04-01 |
| Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (NCT03775525) | Genzada Pharmaceuticals USA, Inc. | 2019-03-01 |
| Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (NCT03888612) | Arvinas Inc. | 2019-03-01 |
| Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial (NCT03658486) | Queen's University, Belfast | 2019-02-19 |
| A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT03575819) | Fortis Therapeutics, Inc. | 2019-02-04 |
| The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients (NCT04776889) | National Cancer Institute, Egypt | 2019-01-15 |
| MGD019 DART® Protein in Unresectable/Metastatic Cancer (NCT03761017) | MacroGenics | 2018-12-12 |
| Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer (NCT03739684) | Progenics Pharmaceuticals, Inc. | 2018-11-27 |
| Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer (NCT03646162) | Veru Inc. | 2018-09-14 |
| Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (NCT03413995) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-09-10 |
| Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer (NCT05078151) | Vall d'Hebron Institute of Oncology | 2018-09-01 |
| Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation As a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial (NCT03655886) | University Hospital, Ghent | 2018-08-15 |
| A Trial of Ipatasertib in Combination With Atezolizumab (NCT03673787) | Institute of Cancer Research, United Kingdom | 2018-08-13 |
| Selective Treatment According to Molecular Subtype of Prostate Cancer (NCT03696186) | Tianjin Medical University Second Hospital | 2018-08-01 |
| 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa) (NCT03490032) | Advanced Accelerator Applications | 2018-05-23 |
| PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (NCT03569241) | University Hospital, Ghent | 2018-04-27 |
| Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (NCT03436485) | Orion Corporation, Orion Pharma | 2018-03-19 |
| Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence (NCT03396874) | University of Michigan | 2018-02-09 |
| Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) (NCT03434158) | Spanish Oncology Genito-Urinary Group | 2018-02-06 |
| A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors (NCT03129139) | Minneamrita Therapeutics LLC | 2017-10-10 |
| Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303) (NCT03414437) | Carolina Research Professionals, LLC | 2017-10-01 |
| Evaluation of the Metastasis and Recurrence of Prostate Cancer (NCT03507595) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2017-09-01 |
| Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel (NCT03295565) | The Netherlands Cancer Institute | 2017-05-07 |
| Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel (NCT02961257) | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | 2017-05-05 |
| Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer (NCT03089099) | Fudan University | 2017-04-24 |
| ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. (NCT02933801) | Swiss Cancer Institute | 2017-03-31 |
| Androgen Deprivation Therapy (ADT) Versus ADT Plus Prostate Cryotherapy for Metastatic Prostate Cancer (mPCa) (NCT03129854) | Sun Yat-sen University | 2017-03-29 |
| Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer (NCT03024216) | University of Hawaii | 2017-02-06 |
| uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer (NCT02964988) | Rigshospitalet, Denmark | 2017-01-01 |
| Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC (NCT02913196) | Weill Medical College of Cornell University | 2016-12-30 |
| Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) (NCT02825628) | DexTech Medical AB | 2016-05-01 |
| Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) (NCT04833517) | Universität des Saarlandes | 2016-01-01 |
| Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (NCT02485691) | Sanofi | 2015-11-09 |
| Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223 (NCT03223727) | The Netherlands Cancer Institute | 2015-10-30 |
| Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide (NCT02815033) | The European Uro-Oncology Group | 2015-07-01 |
| Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide (NCT02379390) | Sanofi | 2015-06-17 |
| A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer (NCT02407054) | Eli Lilly and Company | 2015-04-29 |
| PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide (NCT02814968) | The European Uro-Oncology Group | 2015-02-01 |
| Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223 (NCT03223597) | The Netherlands Cancer Institute | 2015-01-17 |
| A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC (NCT02378870) | DexTech Medical AB | 2015-01-01 |
| Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer (NCT02074137) | Sanofi | 2014-07-01 |
| Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT01718353) | Sanofi | 2013-03-01 |
| Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone (NCT01428219) | University of Michigan Rogel Cancer Center | 2012-02-01 |
| Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (NCT02105675) | SOTIO a.s. | 2012-02-01 |
| Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer (NCT01487863) | Dendreon | 2011-12-01 |
| EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (NCT01360840) | EMD Serono | 2011-04-01 |
| Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer (NCT04452136) | Jeanne Link | |
| Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer (NCT05002465) | Dana Mathews | |